A study presented at a radiology meeting found that FDG-PET/CT has the potential to predict patient response following neoadjuvant chemotherapy for breast cancer. Researchers said the results suggest the assessment could be useful for guiding treatment decisions. The researchers used Sinn scores and two algorithms to measure patient response. An 88% change in maximum standardized uptake value is the appropriate cutoff to distinguish lesions that respond to treatment, they reported.
Published in Brief: